Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    0.00 (0.00%)
Bid:
0.00
Ask:
540.00
Spread: 35.00 (6.931%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

27 Jul 2017 07:00

27 July 2017 – Tate & Lyle PLC

TRADING STATEMENT

This Trading Statement covers the period from 1 April 2017 to 30 June 2017, which is the first quarter of the financial year.

The Group made an encouraging start to the year with profit in constant currency ahead of the comparative period, and volume ahead in both divisions.

In core Speciality Food Ingredients:

North America, where the overall Food and Beverage market remained soft, saw modest volume growth with firmer volume from some larger customers, and also continued to make progress in broadening its customer base. Asia Pacific and Latin America, and Europe, Middle East and Africa delivered strong volume growth.

In the remainder of the Speciality Food Ingredients division, Food Systems volume was in line with the comparative period and SPLENDA® Sucralose performed as expected.

In Bulk Ingredients, the core business performed well driven by solid demand for sweeteners and industrial starches, firm US bulk sweetener margins, and continued strong manufacturing performance. In Commodities, performance was ahead of the comparative period.

Overall, we continue to expect that the Group will make underlying progress in the full year.

END

A conference call will be held today at 07.30am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 10 August 2017.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 3389225#

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170726006037/en/

Copyright Business Wire 2017

Date   Source Headline
21st May 202612:15 pmRNSForm 8.3 - Tate & Lyle plc
21st May 202612:06 pmBUSForm 8.3 - Tate & Lyle
21st May 202611:53 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
21st May 202611:22 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
21st May 202611:13 amRNS20260520_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
21st May 202611:11 amRNS20260520_TATE & LYLE_8.5 EPT RI_UK_MLI
21st May 202611:09 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
21st May 202611:01 amRNSForm 8.3 TATE & LYLE PLC
21st May 202610:28 amRNSForm 8.3 - Tate & Lyle Plc
21st May 20268:29 amRNSForm 8.5 (EPT/RI)
21st May 20267:00 amRNSFinal Results
20th May 20264:28 pmRNSForm 8.5 - Tate & Lyle Plc
20th May 20264:26 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
20th May 20263:27 pmRNSForm 8.3 Tate & Lyle plc
20th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20262:49 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20262:03 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
20th May 20261:52 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20261:28 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20261:22 pmRNSForm 8.3 TATE & LYLE PLC
20th May 202612:26 pmRNSForm 8.3 Tate & Lyle Plc
20th May 202612:05 pmRNSForm 8.3 - Tate & Lyle plc
20th May 202611:59 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
20th May 202611:58 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
20th May 202611:47 amRNSForm 8.3- TATE & LYLZ
20th May 202611:35 amRNS20260519_TATE & LYLE_8.5 EPT RI_UK_MLI
20th May 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle Plc
20th May 202611:02 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
20th May 20269:21 amRNSForm 8.5 (EPT/RI)
20th May 20269:18 amRNSForm 8.3 - Tate and Lyle PLC
20th May 20267:33 amRNSForm 8.5 (EPT/RI) - Amend - Tate & Lyle PLC
19th May 20265:59 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
19th May 20265:51 pmRNSForm 8.3 - Tate & Lyle PLC
19th May 20263:39 pmRNSForm 8.3 TATE & LYLE PLC
19th May 20263:25 pmRNSForm 8.3 - Tate & Lyle PLC
19th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
19th May 20262:08 pmRNSForm 8.3 - Tate & Lyle plc
19th May 20262:00 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
19th May 202611:53 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
19th May 202611:52 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
19th May 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
19th May 202611:08 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
19th May 202611:06 amRNSForm 8.3 Tate & Lyle
19th May 202611:05 amRNSForm 8.3 - Tate & Lyle plc
19th May 202610:53 amBUSForm 8.3 - Tate & Lyle plc
19th May 202610:45 amRNSForm 8.3 - Tate & Lyle PLC
19th May 202610:19 amRNS20260518_TATE & LYLE_8.5 EPT RI_UK_MLI
19th May 20269:32 amRNSForm 8.5 (EPT/RI)
18th May 20265:50 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
18th May 20264:48 pmRNS20260514_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.